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Background
• Combined oral contraceptives (COCs) increase the risk of venous 
thromboembolisms (VTE) by 247%2,3,5-9 
• Progestin-only releasing intrauterine devices have a decreased VTE 
risk with an odds ratio of 0.6 compared to 0.7-1.5 for nonusers.2,10,11
• Estrogen dose and progestin type in COCs can increase VTE risk by 
20% and 30%, respectively2,3,8
• VTEs have the highest risk in developing in the first 12 months of 
initiating therapy with COCs, especially in women under age 30, 
compared to use of 5 years or greater2,4,8,12 
• Drug routes for combined hormonal contraceptives do not impact risk 
of developing VTEs3,4
• Risk factors such as age over 35, obesity, smoking, and family 
history of VTE are considered when prescribing2,8,12,13,14 
Oral contraceptives are the most commonly 
used birth control method for women under 
301 Studies have shown an increased risk of 
venous thromboembolisms, commonly 
referred to as blood clots, with the use of 
combined oral contraceptives in comparison 
to progestin-only forms2-4
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For women aged 20-35, does the use of oral 
contraceptives increase the risk of blood clot 
development compared to other forms of 
contraception over a period of 5 years?





Through education and 
encouragement on modifying risk 
factors, women who have begun 
contraceptives will experience 
decreased complications of VTE in the 
first year of use.
Implement the VTE Prevention Program
• Present relative and absolute risks of VTE, as risk is increased with 
use, but overall occurrence is low and advantages may outweigh 
risks15
• Encourage smoking cessation. 
• Provide weight management education for women with a BMI > 30.
• Consult with the provider for alternative contraception options for 
women over 35.
• Encourage women under 30 to be vigilant for signs of VTE during 
their first year of use.
• Notify the provider if the following signs and symptoms of 
complications occur:
• Deep vein thrombosis: unilateral calf swelling, leg pain, leg warmth 
and redness16
• Pulmonary embolism: shortness of breath, chest pain, blood-
tinged cough16
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We screened 16 journal articles and retained 
13 articles based on the quality evaluation 
rubric and this is the criteria that we used: 
• Databases: Academic Search Complete, 
PubMed, CINAHL
• Keywords: combined oral contraceptive, 
hormonal contraceptive, thromboembolism, 
progestin 
• Article Criteria: Peer-reviewed journals 
published between 2015 to 2020.
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